Glibenclamide

Malignant Edema

Remedy Pharmaceuticals, Inc.Small moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

2 Active assets in the Malignant Edema cohort.

Asset / Sponsor	Phase	Rating
Sodium Aescinate The Second Hospital of Hebei Medical University	Phase 4	BB
DEXAMETHASONE Jon Pérez Bárcena	Phase 3	B
Conivaptan Jesse Corry	Phase 2	B
PANTOPRAZOLE University of Florida	Phase 2	B
MANNITOL University of Florida	Phase 2	B

View all 13 →

Same molecule, other indications

Glibenclamide is also rated in:

diabetes mellitusDormant

BBB

Indicative ·

76 / 100

essential hypertensionDormant

BB

Indicative ·

69 / 100

hypertrophic cardiomyopathyDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.